| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US4996335 (Pediatric) | BAUSCH AND LOMB | Soft steroids having anti-inflammatory activity |
Sep, 2012
(11 years ago) | |
| US5540930 | BAUSCH AND LOMB | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Oct, 2013
(10 years ago) | |
| US5747061 | BAUSCH AND LOMB | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Oct, 2013
(10 years ago) | |
|
US5540930 (Pediatric) | BAUSCH AND LOMB | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Apr, 2014
(10 years ago) | |
|
US5747061 (Pediatric) | BAUSCH AND LOMB | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Apr, 2014
(10 years ago) | |
Zylet is owned by Bausch And Lomb.
Zylet contains Loteprednol Etabonate; Tobramycin.
Zylet has a total of 5 drug patents out of which 5 drug patents have expired.
Expired drug patents of Zylet are:
- US4996335*PED
- US5540930
- US5747061
- US5540930*PED
- US5747061*PED
Zylet was authorised for market use on 14 December, 2004.
Zylet is available in suspension/drops;ophthalmic dosage forms.
Zylet can be used as steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists.
The generics of Zylet are possible to be released after 25 April, 2014.
Drugs and Companies using LOTEPREDNOL ETABONATE; TOBRAMYCIN ingredient
Market Authorisation Date: 14 December, 2004
Treatment: Steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists
Dosage: SUSPENSION/DROPS;OPHTHALMIC
ZYLET family patents
